Necrotizing Enterocolitis Market Report 2026

The necrotizing enterocolitis market size has grown strongly in recent years. It will grow from $5.14 billion in 2025 to $5.47 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to high incidence of premature births, limited neonatal care infrastructure, reliance on broad-spectrum antibiotics, delayed diagnosis in low-resource settings, early development of parenteral nutrition.

The necrotizing enterocolitis market size is expected to see strong growth in the next few years. It will grow to $6.95 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising investment in neonatal intensive care units, advancements in regenerative and stem cell therapies, increasing awareness of early nec detection, growing adoption of precision nutrition therapies, expansion of neonatal imaging innovations. Major trends in the forecast period include rising adoption of probiotics and prebiotics for nec prevention, increased focus on early diagnosis and screening in premature infants, growing utilization of individualized tpn solutions, expansion of minimally invasive surgical interventions, advancements in neonatal critical care and monitoring.

The rising incidence of premature births is expected to drive the growth of the necrotizing enterocolitis (NEC) market. Premature births, defined as deliveries before 37 weeks of gestation, occur more frequently due to maternal health conditions such as hypertension, diabetes, and infections, as well as lifestyle factors including smoking, poor nutrition, and substance use. Preterm infants are particularly susceptible to NEC because of their underdeveloped gastrointestinal systems, which increases vulnerability to inflammation and infection. For instance, in January 2024, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that premature births account for 8.67% of total births in the United States annually. Therefore, the increasing prevalence of premature births is driving the NEC market.

Advancements in innovative treatments are also shaping the NEC market. Major companies are focusing on cell-free sterile biologic solutions to meet the critical need for effective therapies in premature infants. These solutions are sterile liquids containing bioactive molecules such as proteins, growth factors, and cytokines derived from cultured cells, designed to reduce inflammation and promote intestinal healing without using intact cells. For example, in December 2023, Noveome Biotherapeutics, Inc., a US-based biopharmaceutical company, received FDA clearance to proceed with Phase 1-2 clinical trials for ST266, a novel biologic targeting NEC in premature infants. ST266 represents the first major therapeutic advancement for NEC in over 30 years, addressing a disease with high morbidity and mortality in vulnerable populations.

In January 2025, Siolta Therapeutics, a US-based developer of live biotherapeutics for NEC, partnered with Cowellnex Co., a US-based biotechnology company, to prevent NEC in premature infants. This collaboration leverages Siolta's Precision Symbiotics Platform alongside Cowellnex’s institutional capabilities to advance microbiome-based drug discovery and establish novel preventive treatments. These initiatives highlight the growing focus on innovative therapies and collaborative approaches to address NEC in preterm populations.

Major companies operating in the necrotizing enterocolitis market are Abbott Laboratories, Astellas Pharma Inc., Mayo Foundation for Medical Education and Research, Cleveland Clinic, Boston Children's Hospital, Hollister Incorporated, UPMC Children's Hospital of Pittsburgh, Prolacta Bioscience Inc., Evolve BioSystems, Sigma-Tau Pharmaceuticals, Mead Johnson & Company LLC, Liminal BioSciences Inc., Noveome Biotherapeutics Inc., Infant Bacterial Therapeutics, Prometic Life Sciences Inc., Nexilico, Siolta Therapeutics, ProThera Biologics Inc., Plakous Therapeutics Inc., Chosen Diagnostics Inc.

North America was the largest region in the necrotizing enterocolitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the necrotizing enterocolitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the necrotizing enterocolitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on medical devices, neonatal care equipment, and imported pharmaceutical components have contributed to increased treatment and diagnostic costs in the necrotizing enterocolitis market. Regions heavily reliant on imported neonatal tools - such as Europe and North America - experience the largest pricing fluctuations. Specialized equipment for TPN, imaging, and antimicrobial therapies is most affected. However, tariffs may stimulate domestic manufacturing, strengthen local supply chains, and support innovation in cost-efficient neonatal care technologies.

The necrotizing enterocolitis market research report is one of a series of new reports that provides necrotizing enterocolitis market statistics, including necrotizing enterocolitis industry global market size, regional shares, competitors with a necrotizing enterocolitis market share, detailed necrotizing enterocolitis market segments, market trends and opportunities, and any further data you may need to thrive in the necrotizing enterocolitis industry. This necrotizing enterocolitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Necrotizing enterocolitis (NEC) is a severe, potentially life-threatening gastrointestinal disorder that primarily affects premature infants. It involves inflammation and necrosis of intestinal tissue, which can lead to perforation, infection, and other serious complications. Common symptoms include feeding intolerance, abdominal distension, vomiting, and changes in bowel movements.

The main treatment types for necrotizing enterocolitis include total parenteral nutrition (TPN), gastrointestinal decompression, antimicrobial therapy, antifungal treatment, paracentesis, and other interventions. TPN provides nutrients directly into the bloodstream, allowing the intestines to rest and heal. NEC is diagnosed using laboratory tests and imaging techniques and classified into stages, including stage I (suspected), stage II (definite), and stage III (advanced). Treatments are distributed through direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and other channels, and are used by end users such as hospitals, neonatal intensive care units (NICUs), and specialty clinics.

The necrotizing enterocolitis market consists of revenues earned by entities providing services such as neonatal intensive care, nutritional support, medical monitoring and support, and parental counseling and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The necrotizing enterocolitis market also includes sales of feeding tubes, surgical instruments for resection, and anti-inflammatory drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.